SAN FRANCISCO, July 16, 2018 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a commercial-stage
biopharmaceutical company focused on saving and improving the lives
of pets, today announced that it will release its second quarter
2018 financial results on August 9,
2018 after the market close. The Company will host a
conference call at 4:30 p.m. Eastern
Time / 1:30 p.m. Pacific Time
that day.
Interested parties may access the call by dialing toll-free
(855) 433-0927 from the US, or (484) 756-4262 internationally, and
using conference ID 4789665.
The call will also be webcast live here, with a replay available
at that link for 30 days.
About Kindred Biosciences
Kindred Biosciences is a commercial-stage biopharmaceutical
company focused on saving and improving the lives of pets. Its
mission is to bring to pets the same kinds of safe and effective
medicines that human family members enjoy. The Company's strategy
is to identify compounds and targets that have already demonstrated
safety and efficacy in humans and to develop therapeutics based on
these validated compounds and targets for dogs, cats and horses.
The Company has a deep pipeline of novel drugs and biologics in
development across many therapeutic classes. KindredBio's first
approved drug is Mirataz® (mirtazapine transdermal ointment)
for the management of weight loss in cats.
For more information or to download the corporate presentation,
visit www.KindredBio.com/LearnMore. Stay connected with KindredBio
on Facebook at www.Facebook.com/KindredBio.
Contacts
For investor inquiries:
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
For media inquiries:
Jeanene Timberlake
jtimberlake@rooneyco.com
(646) 770-8858
View original content with
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-announce-second-quarter-2018-financial-results-300680698.html
SOURCE Kindred Biosciences, Inc.